Double-blind, randomized phase III study to compare the efficacy and safety of CT-P6, trastuzumab biosimilar candidate versus trastuzumab as neoadjuvant treatment in HER2 positive early breast cancer (EBC). (2017)
Attributed to:
Identification, roles and mechanisms of long non-coding RNAs in stem cells and metastasis in breast cancer.
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1200/jco.2017.35.15_suppl.510
Publication URI: http://dx.doi.org/10.1200/jco.2017.35.15_suppl.510
Type: Journal Article/Review
Parent Publication: Journal of Clinical Oncology
Issue: 15_suppl